Rapamycin Analogs for Stent-Based Local Drug Delivery: Everolimus- and Tacrolimus-Eluting Stents

Herz

Volumn 29, Issue 2, 2004, Pages 162-166

  Grube, Eberhard ^a   Buellesfeld, Lutz ^a  

^a Heart Center Siegburg   (Germany)

Author keywords

Coronary artery disease; Drug eluting stents; Everolimus; New device; Tacrolimus

Indexed keywords

CLOPIDOGREL; EVEROLIMUS; POLYHYDROXYACID; POLYMER; RAPAMYCIN DERIVATIVE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SAFETY; HUMAN; INTRAVASCULAR ULTRASOUND; NONHUMAN; REVIEW; SENSITIVITY ANALYSIS; SMOOTH MUSCLE FIBER;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY STENOSIS; CORONARY VESSELS; FEASIBILITY STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TACROLIMUS; TREATMENT OUTCOME;

EID: 1942424170     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2556-6     Document Type: Review

References (12)

1. Kahan HD, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999;68:1100-6.
2. Nashan B. The role of everolimus (everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001;33:3215-20.
3. Honda H, Kar S, Honda T, et al. Everolimus-eluting stents significantly inhibit neointimal hyperplasia in an experimental pig coronary model. Presented at TCT, Washington, September 15-19, 2003.
4. Grube E. Clinical results from Future I and "Future" plans. Presented at EuroPCR, Paris, May 20-23, 2003.
5. Costa RA, Lansky AJ, Mehran R, et al. Everolimus-eluting stent for the treatment of de novo coronary lesions: angiographic follow-up of the FUTURE trial. Presented at TCT, Washington, September 15-19, 2003.
6. Sonoda S, Grube E, Ikeno F, et al. Everolimus-eluting stents are effective in preventing neointimal hyperplasia regardless of the vessel diameter: an intravascular ultrasound subanalysis of the FUTURE I trial. Presented at TCT, Washington, September 15-19, 2003.
7. Grube E. FUTURE II: multicenter Evaluation of the bioabsorbable polymer-based everolimus-eluting stent. Presented at TCT, Washington, September 15-19, 2003.
8. Matter MC, Wnendt S, Kurz DJ, et al. Tacrolimus, but not sirolimus targets human vascular smooth muscle cells, but spares endothelial cells - implications for drug-eluting stents. Eur Heart J 2002;4:Suppl:143.abstract.
9. Mohacsi PJ, Tüller D, Hulliger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997;16:484-92.
10. Schächinger V, Baldus S, Münzel T, et al. A randomized trial of PTFE-membrane covered stents compared to conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003;42:1370-2.
11. Grube E. Final tacrolimus outcomes in native coronaries and saphenous vein grafts: PRESENT & EVIDENT. Presented at the ACC Meeting, Chicago, March 30 - April 2, 2003.
12. Scheller B. Preclinical evaluation of tacrolimus stent coating. In: Stone G, ed. Textbook of coronary stenting. 2004: in press.